Ebglyss (lebrikizumab-lbkz) — Medica

Initial criteria

• Patient is ≥ 18 years of age OR patient is 12 to 17 years of age AND weighs ≥ 40 kg
• Atopic dermatitis involvement estimated to be ≥ 10% of body surface area according to the prescriber
• Patient has tried at least one medium-, medium-high-, high-, and/or super-high-potency prescription topical corticosteroid applied daily for at least 28 consecutive days AND had inadequate efficacy according to the prescriber
• Medication is prescribed by or in consultation with an allergist, immunologist, or dermatologist

Reauthorization criteria

• Patient has already received at least 4 months of therapy with Ebglyss
• Patient has responded to therapy as determined by the prescriber (e.g., improvement in erythema, induration/papulation/edema, excoriations, lichenification, pruritus, reduced need for other therapies, or decreased body surface area affected)

Approval duration

initial: 4 months; reauthorization: 1 year